Acorda Therapeutics is a commercial stage biopharmaceutical company identifying and developing treatments for neurological disorders including multiple sclerosis, spinal cord injury and disorders of the nervous system.
Established in 1995 to address the lack of CNS treatments available, Acorda Therapeutics employs over 200 professionals and tailors its developments by maintaining an ‘open dialogue’ with its patients whereby it constantly keeps in touch with them to ensure all its products are based on their needs. Acorda scientists feel that patient satisfaction is the best reward to all its efforts.
Wholeheartedly committed to creating therapies that improve or restore neurological functions, Acorda develops therapies that;
Protect brain or spinal cord nerves that have been damaged by injury
Regenerate neural connections
Address damage to loss of myelin which is the fibres that surround the nerves.
The company has 10 products in total, three of which are on the market, one that is at phase 3/4 and another is in the R&D phase. Acorda’s main product is AMPYRA®, a US approved product that improves walking in Multiple Sclerosis patients. The success of this product has really put Acorda Therapeutics on the map and allowed the company to develop and create similar products. The other two products on the market are Zaraflex capsules® for the treatment of spascity and Qutenza® for the treatment of post shingles nerve pain.
Partnering at the clinical stage
Acorda Therapeutics cleverly says that collaboration remains an important part of its DNA.
Over the past five years the company has made over 10 partnership deals, many of which are with a number of academic partners and interestingly at the clinical stage of development. Five of the deals were directly based around MS which is one of the company’s target disease areas.
Through these partnerships Acorda aims to advance the care of people affected by neurological diseases. For potential partners Acorda offers scientific, regulatory and commercial expertise. This is then combined with its willingness to create collaborations and harmonise partnerships. Together these attributes make Acorda a very attractive candidate.
To contact Acorda Therapeutics for any potential research and development ideas or you can find a contact email address on this page. Therapeutically the company is interested in partnering with companies who have neurologically focused products.
Partnering outreach
Acorda Therapeutics is often present at a large number of partnering events throughout the year. Partnering events are a great place to meet lots of potential partners face to face in a short space of time.
Events with Acorda Therapeutics presence include but are not limited to:
BIO International Convention and Business Forum
BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with Acorda Therapeutics in person visit Current Partnering’s Event calendar.
Contacting Acorda Therapeutics for partnering
Acorda Therapeutics can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with Acorda Therapeutics’ business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. This page on the Acorda Therapeutics website has details for contacting Acorda Therapeutics.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.
Many of Acorda Therapeutics’ business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Acorda Therapeutics Linkedin Page.
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. This is the contacts page on the Acorda Therapeutics website for potential partnering opportunities and general contact names.
Raveena Bhambra
* www.acorda.com
More
Summary profile data for Acorda Therapeutics
Partnering activity for Acorda Therapeutics
M&A activity for Acorda Therapeutics
View all partnering deals for Acorda Therapeutics: 2014 | 2013 | 2012 | 2011 | 2010 | 2009
Full details on each deal can be found at CurrentAgreements (subscription required)
Available reports from Current Partnering
Report: Partnering Agreements with Acorda Therapeutics 2009-2014
Report: Partnering Deals and Alliances with Big Biotech
Available resources for deal coverage for Acorda Therapeutics
Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more
Read: more on Acorda Therapeutics company profile, recent partnering, M&A and financing news and articles
Related
Report: Practical Guide to Finding Partners
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now
Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter
The post Acorda Therapeutics: Maintaining an open patient dialogue to treat neurological diseases appeared first on .